Latest debt-to-equity ratio
Halozyme Therapeutics Debt-to-equity ratio
Direct answer
Halozyme Therapeutics's debt-to-equity ratio is 1,517.69%.
The verified market snapshot reports 1,517.69%.
Bullstory displays the reported value and does not estimate missing data.
Market data checked October 26, 2026.
Get free Halozyme Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Debt-to-equity ratio
- 1,517.69%
Explore related company data
View Halozyme Therapeutics's market capitalizationView Halozyme Therapeutics's p/e ratioView Halozyme Therapeutics's price-to-book ratioView Halozyme Therapeutics's return on equityView Halozyme Therapeutics's dividend yieldView Halozyme Therapeutics's 52-week price rangeView Halozyme Therapeutics's revenue growthView Halozyme Therapeutics's profit marginView all Halozyme Therapeutics key metricsReturn to Halozyme Therapeutics profile